Table 2.
Correlation of anti-PF4 antibodies with demographic, clinical, and laboratory parameters in hospitalized patients with COVID-19
| Regression analyses and parameters | |||
|---|---|---|---|
| Linear regression analysis Age |
Pearson’s correlation −0.1384 |
95% CI −0.33 to 0.06 |
P value 0.1698 |
| Sex | — | — | 0.0126 |
| Race | — | — | 0.0312 |
| Ethnicity | — | — | 0.0059 |
| BMI | −0.0655 | −0.26 to 0.13 | 0.5172 |
| C-reactive protein | 0.1406 | −0.07 to 0.34 | 0.1992 |
| D-dimer | 0.1709 | −0.05 to 0.38 | 0.1296 |
| White blood cells | 0.2491 | 0.04 to 0.44 | 0.0223 |
| Ferritin | −0.0687 | −0.49 to 0.37 | 0.7672 |
| Lactic dehydrogenase | 0.3920 | −0.13 to 0.74 | 0.1332 |
| Platelet reduction | 0.3678 | 0.17 to 0.54 | 0.0004 |
| Intravenous heparin treatment | — | — | 0.1482 |
| Maximum disease severity score | 0.2910 | 0.10 to 0.46 | 0.0033 |
| Multiple regression analysis | Estimate | SE | P value |
| Intercept | 0.7938 | 0.3742 | 0.0366 |
| Age | −0.0034 | 0.0030 | 0.2564 |
| Race | |||
| White | −0.0610 | 0.2833 | 0.8301 |
| Black | 0.0508 | 0.2835 | 0.8581 |
| Other | 0.1798 | 0.2863 | 0.5317 |
| Intravenous heparin treatment | 0.0506 | 0.0938 | 0.5912 |
| BMI | −0.0037 | 0.0049 | 0.4514 |
| Maximum disease severity score | 0.0482 | 0.0197 | 0.0163 |